Addiction, EarlyView.Abstract Background and aims Alcohol use disorder (AUD) follows a chronic, relapsing course but is often overlooked when alcohol consumption is minimal at the time of evaluation. We aimed to assess the prognostic impact of a prior AUD diagnosis on liver‐related outcomes in patients with presumed metabolic dysfunction‐associated steatotic liver disease (
Butros Fakhoury +6 more
wiley +1 more source
Exploring Disease-Specific Waitlist Outcomes in Simultaneous Liver-Kidney Transplantation. [PDF]
Transpl IntOki R +5 more
europepmc +1 more source
The Bidirectional Association Between MASLD and Male Hypogonadism: An Updated Meta‐Analysis
Andrology, EarlyView.ABSTRACT Background Metabolic dysfunction‐associated steatotic liver disease (MASLD) and male hypogonadism are increasingly prevalent, metabolically interrelated conditions. Testosterone (T) deficiency has been implicated in hepatic lipid dysregulation, insulin resistance, and visceral adiposity, whereas MASLD may impair the hypothalamic–pituitary ...
Giorgia Spaggiari +9 more
wiley +1 more source
Impact of Glucagon-Like Peptide-1 Receptor Agonists on Liver-Related Outcomes, Laboratory and Physiologic Parameters in Metabolic Dysfunction-Associated Steatohepatitis: A Systematic Review and Meta-Analysis. [PDF]
Diabetes Metab Syndr ObesWang MJ, Jiang YN, Li PP, Wu YJ.
europepmc +1 more source
Alimentary Pharmacology &Therapeutics, EarlyView.Metabolic dysfunction‐associated steatohepatitis is the second commonest US indication for liver transplantation but remains largely undiagnosed and untreated. Fibrosis stage is the strongest predictor of major adverse liver outcomes, with decompensation rates and transplant‐free survival diverging sharply between F3 and F4, while cardiovascular ...
Malek Ayoub +2 more
wiley +1 more source
Changes in Coagulation Parameters and Metabolic Profile in Hospitalized Patients with Metabolic Dysfunction-Associated Steatohepatitis Receiving Vitamin K: A Retrospective Observational Study. [PDF]
Clin PractLixandru M +3 more
europepmc +1 more source
Is there a role for cannabidiol in obesity, metabolic syndrome and binge eating?
British Journal of Pharmacology, EarlyView.Cannabidiol (CBD) is one of the most abundant phytocannabinoids isolated from the Cannabis sativa plant. CBD is a lipophilic, non‐intoxicating substance that differently from Δ9‐tetrahydrocannabinol (Δ9‐THC) does not present the typical profile of a drug of abuse.
Luca Botticelli +7 more
wiley +1 more source
Impact of incretin analogues on lipid and lipoprotein metabolism in obesity and diabetes
British Journal of Pharmacology, EarlyView.Abstract Incretin‐based therapies have gained momentum as a key strategy for reducing cardiovascular risk in individuals with obesity and/or type 2 diabetes (T2D). It remains unclear whether the cardiovascular benefits reflect a direct reduction in atherogenic lipoproteins—namely, low‐density lipoproteins (LDL), very low‐density lipoproteins (VLDL) and
Andrea Baragetti, Giuseppe Danilo Norata
wiley +1 more source
Efficacy and safety of efruxifermin for patients with NASH/MASH: an updated systematic review and meta-analysis. [PDF]
Front PharmacolXiao YJ +7 more
europepmc +1 more source
British Journal of Pharmacology, EarlyView.Obesity is a chronic, relapsing, multisystem disease in which cardiometabolic risk arises from excess adiposity and progressive dysfunction of peripheral organs, ultimately disrupting endocrine and metabolic crosstalk among tissues. Within this network, sulphur‐based biology, centred on hydrogen sulphide and related reactive sulphur species, has ...
Martina Smimmo +4 more
wiley +1 more source